SEARCH

SEARCH BY CITATION

References

  • 1
    Office for National Statistics. Cancer Statistics: Registrations. Registrations of Cancer Diagnosed in 1991, England and Wales. Series MB 1, No. 24. London : HMSO, 1997.
  • 2
    Burger HG, Baillie A, Drummond AE et al. Inhibin and ovarian cancer. J Reprod Immunol 1998; 39: 7787.
  • 3
    Healy DL, Burger HG, Mamers P et al. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med 1993; 329: 15391542.
  • 4
    Blaakaer J, Micie S, Morris ID et al. Immunoreactive inhibin-production in postmenopausal women with malignant epithelial ovarian tumors. Eur J Obstet Gynecol Reprod Biol 1993; 52: 105110.
  • 5
    Lambert-Messerlian GM, Steinhoff M, Zheng W et al. Multiple immunoreactive inhibin proteins in serum from postmenopausal women with epithelial ovarian cancer. Gynecol Oncol 1997; 65: 512516.
  • 6
    Burger HG, Robertson DM, Cahir N et al. Characterization of inhibin immunoreactivity in post-menopausal women with ovarian tumours. Clin Endocrinol (Oxf) 1996; 44: 413418.
  • 7
    Cooke I, O'Brien M, Charnock FM, Groome N, Ganesan TS. Inhibin as a marker for ovarian cancer. Br J Cancer 1995; 71: 10461050.
  • 8
    Petraglia F, Luisi S, Pautier P et al. Inhibin B is the major form of inhibin/activin family secreted by granulosa cell tumors. J Clin Endocrinol Metab 1998; 83: 10291032.
  • 9
    Groome NP, Illingworth PJ, O'Brien M, Priddle J, Weaver K, Mcneilly AS. Quantification of inhibin pro αC-containing forms in human serum by a new ultrasensitive two-site enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 1995; 80: 29262932.
  • 10
    Welt CK, Lambert-Messerlian G, Zheng W, Crowley WF Jr, Schneyer AL. Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma. J Clin Endocrinol Metab 1997; 82: 37203727.
  • 11
    St Bartholomew's/Royal London Randomised Control Trial of Ovarian Cancer Screening (protocol) (1999). Ovarian Cancer Screening Unit, St Bartholomew's and the Royal London School of Medicine and Dentistry, London , UK .
  • 12
    Burger HG, Cahir N, Robertson DM et al. Serum inhibins A, B fall differentially as follicle stimulating hormone rises in perimenopausal women. Clin Endocrinol (Oxf) 1998; 48: 809813.
  • 13
    Loria P, Petraglia F, Concari M et al. Influence of age and sex on serum concentrations of total dimeric activin. Eur J Endocrinol 1998; 139: 487492.
  • 14
    Sakamoto Y, Shintani Y, Harada K, Abe M, Shitsukawa K, Saito S. Determination of free follistatin levels in sera of normal subjects and patients with various diseases. Eur J Endocrinol 1996; 35: 345351.
  • 15
    Groome NP, Illingworth PJ, O'Brien M et al. Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay. Clin Endocrinol 1994; 40: 717723.
  • 16
    Knight PG, Muttukrishna S, Groome NP. Development and application of a two-site enzyme immunoassay for the determination of ‘total’ activin-A concentrations in serum and follicular fluid. J Endocrinol 1996; 148: 267279.
  • 17
    Evans LW, Muttukrishna S, Groome NP. Development, validation and application of an ultra-sensitive two-site enzyme immunoassay for human follistatin. J Endocrinol 1998; 156: 275282.
  • 18
    Riley SC, Wathen NC, Chard T, Groome NP, Wallace EM. Inhibin in extra-embryonic coelomic and amniotic fluids and maternal serum in early pregnancy. Hum Reprod 1996; 11: 27722776.
  • 19
    Riley SC, Balfour C, Evans LW et al. Follistatin and activin A in extraembryonic coelomic and amniotic fluids and maternal serum in early pregnancy. Hum Reprod 1998; 13: 26242628.
  • 20
    Knight PG, Muttukrishna S. Measurement of dimeric inhibin using a modified two-site immunoradiometric assay specific for oxidised (Met O) inhibin. J Endocrinol 1994; 141: 417425.
  • 21
    McFarlane JR, Foulds LM, Pisciotta A et al. Measurement of activin in biological fluids by radioimmunoassay, utilising dissociating agents to remove the influence of follistatin. Eur J Endocrinol 1996; 134: 481489.
  • 22
    Robertson DM, Cahir N, Burger HG, Mamers P, Groome N. Inhibin forms in serum from postmenopausal women with ovarian cancer. Clin Endocrinol 1999; 50: 381386.
  • 23
    Frias AE Jr, Li H, Keeney GL, Podratz KC, Woodruff TK. Preoperative serum level of inhibin A is an independent prognostic factor for the survival of postmenopausal women with epithelial ovarian cancer. Cancer 1999; 85: 465471.
  • 24
    Robertson DM, Cahir N, Burger HG et al. Combined inhibin and CA 125 assay in the detection of ovarian cancer. Clin Chem 1999; 45: 651658.
  • 25
    Lambert-Messerlian GM, De Pasquale SE, Maybruck WM, Steinhoff MM, Gajewski WH. Secretion of activin A in recurrent epithelial ovarian cancer. Gynecol Oncol 1999; 74: 9397.
  • 26
    Di Simone N, Crowley WF Jr, Wang QF, Sluss PM, Schneyer AL. Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology 1996; 137: 486494.
  • 27
    Zheng W, Luo MP, Welt C et al. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. Gynecol Oncol 1998; 69, 2331.
  • 28
    Arora DS, Cooke IE, Ganesan TS et al. Immunohistochemical expression of inhibin/activin subunits in epithelial and granulosa cell tumours of the ovary. J Pathol 1997; 181: 413418.
  • 29
    Di Simone N, Hall HA, Welt C, Schneyer AL. Activin regulates beta A-subunit and activin receptor messenger ribonucleic acid and cellular proliferation in activin-responsive testicular tumor cells. Endocrinology 1998; 139: 11471155.
  • 30
    Wang QF, Khoury RH, Smith PC et al. A two-site monoclonal antibody immunoradiometric assay for human follistatin: secretion by a human ovarian teratocarcinoma-derived cell line (PA-1). J Clin Endocrinol Metab 1996; 81: 14341441.
  • 31
    Khoury RH, Wang QF, Crowley WF Jr et al. Serum follistatin levels in women: evidence against an endocrine function of ovarian follistatin. J Clin Endocrinol Metab 1995; 80: 13611368.
  • 32
    Schneyer Al, Hall HA, Lambert-Messerlian G, Wang QF, Sluss P, Crowley WF Jr. Follistatin-activin complexes in human serum and follicular fluid differ immunologically and biochemically. Endocrinology 1996; 137: 240247.
  • 33
    Blaakaer J, Djursing H, Hording U et al. The pituitary-gonadal axis in women with benign or malignant ovarian tumors. Acta Endocrinol 1992; 127: 127130.
  • 34
    Mahlck CG, Grankvist K, Kjellgren O et al. Human chorionic gonadotrophin, follicle-stimulating hormone, and luteinizing hormone in patients with epithelial ovarian carcinoma. Gynecol Oncol 1990; 36: 219225.
  • 35
    Blaakaer J, Hogdall CK, Micic S et al. Ovarian carcinoma serum markers and ovarian steroid activity—is there a link in ovarian cancer? A correlation of inhibin, tetranectin and CA-125 to ovarian activity and the gonadotrophin levels. Eur J Obstet Gynecol Reprod Biol 1995; 59: 5356.